Listed by the USPTO as CABRAL, ROBERT S
Tech Center 1600 • Art Units: 1614 1618
This examiner grants 63% of resolved cases
CABRAL, ROBERT S handles cases in USPTO Technology Center 1600 and art unit 1614. The profile records 870 resolved cases and a 62.8% allowance rate. The median time to allowance is 2030 days, making prosecution duration a particularly important consideration for applicants, counsel, and business teams.
The reported interview lift is 32.3%, supporting direct examiner engagement as part of a sustained strategy. The listed companies are L.E.A.F. Holdings Group LLC, Winfield Solutions LLC, and Hoffmann-La Roche Inc. DORSEY & WHITNEY LLP - Minneapolis, NIXON & VANDERHYE, PC, and AMSTER, ROTHSTEIN & EBENSTEIN LLP are the identified firms. Applicants should prepare for extended prosecution with strong written support, targeted amendments, and deliberate decisions about continuation and claim prioritization.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18014729 | ANTIBODIES WHICH BIND TO CANCER CELLS AND TARGET RADIONUCLIDES TO SAID CELLS | Non-Final OA | Hoffmann-La Roche Inc. |
| 17998761 | CARBON NANOTUBES AND COMPLEXES THEREOF FOR TREATING AND DETECTING OCULAR TUMORS | Final Rejection | THE REGENTS OF THE UNIVERSITY OF MICHIGAN |
| 18022670 | COMPOSITION COMPRISING POLYETHYLENE GLYCOL CONJUGATED TO INDOCYANINE GREEN AND METHODS OF USE | Non-Final OA | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM |
| 18908740 | ULTRASMALL NANOPARTICLES AND METHODS OF MAKING AND USING SAME | Non-Final OA | CORNELL UNIVERSITY |
| 18920438 | NANOSTRUCTURED SURFACES | Non-Final OA | Brown University |
| 18272110 | CAVITATION AGENT | Final Rejection | Oxford University Innovation Limited |
| 18426838 | Microencapsulation of Active Agents | Non-Final OA | Temple University-Of The Commonwealth System of Higher Education |
| 17725544 | COMBINATION RADIOIMMUNOTHERAPY AND CD47 BLOCKADE IN THE TREATMENT OF CANCER | Non-Final OA | ACTINIUM PHARMACEUTICALS, INC. |
| 18751742 | Formulated and/or Co-Formulated Liposome Compositions Containing PD-1 Antagonist Prodrugs Useful in the Treatment of Cancer and Methods Thereof | Non-Final OA | Nammi Therapeutics, Inc. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy62.8% of resolved applications examined by Robert S Cabral were allowed (870 resolved cases), compared with 47.9% across Art Unit 1614 over the last five years.
This examiner's interview lift is +32.3 percentage points: the difference in allowance rate between resolved applications that had an examiner interview and those that did not.
Applications allowed by Robert S Cabral took 2,030 days on average from filing to allowance.
Robert S Cabral examines applications in Art Unit 1614 in Tech Center 1600 (Biotechnology & Pharmaceuticals).
